Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 5/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 9/20 | 0.41 |
| ▸ | LGMN | Q99538 | 1/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL991941 | 0.82 | F10 (0.51) | F10PTGS2LGMNPIK3CDPIK3CA | |
| SCHEMBL1028503 | 0.81 | F10 (0.48) | F10PTGS2LGMNPIK3CDPIK3CA | |
| SCHEMBL31347248 | 0.81 | F10 (0.48) | F10PTGS2LGMNPIK3CDPIK3CA | |
| SCHEMBL5628988 | 0.81 | MAPT (0.45) | F10PTGS2 | |
| SCHEMBL19178457 | 0.78 | F10 (0.51) | F10PTGS2LGMNPIK3CDPIK3CA | |
| SCHEMBL2996200 | 0.78 | PTGS2 (0.50) | F10PTGS2PIK3CDPIK3CAPIK3CG | |
| SCHEMBL24195918 | 0.78 | F10 (0.48) | F10PTGS2PIK3CDPIK3CAPIK3CG | |
| SCHEMBL5625256 | 0.76 | F10 (0.43) | F10PTGS2 | |
| SCHEMBL5626035 | 0.76 | F10 (0.43) | F10PTGS2 | |
| SCHEMBL15330927 | 0.76 | F10 (0.46) | F10PTGS2LGMNPIK3CDPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070179122-A1 | Beta-Aminoacid-Derivatives As Factor Xa Inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-08-02 | — | — | US | disclosed |
| EP-1723164-A1 | BETA-AMINOACID-DERIVATIVES AS FACTOR Xa INHIBITORS | Sanofi-Aventis Deutschland GmbH (DE) | 2006-11-22 | — | — | EP | disclosed |
| WO-2005095440-A1 | BETA-AMINOACID-DERIVATIVES AS FACTOR Xa INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179122-A1 | Beta-Aminoacid-Derivatives As Factor Xa Inhibitors | F12, F11, F5 | F10 9/4885PTGS2 2409/4885LGMN 1844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.